The novel approach of the medication represents a significant advance in the handling of type 2 diabetes. Distinct from existing medications, tirzepatide affects dual pathways – GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) – providing greater glucose control and potential weight loss